Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Perrigo Company (PRGO - Analyst Report) recently announced that it is set to acquire a UK-based privately held pharmaceutical company, Rosemont Pharmaceuticals Ltd. and has entered into a definitive merger agreement for the same. The deal is valued at $283 million.

By acquiring Rosemont Pharma, Perrigo aims to strengthen its position in the UK oral liquid formulations space. Rosemont Pharma boasts of a portfolio of more than 90 products. The company generated net sales of more than $60 million in 2012.

The deal is expected to boost Perrigo’s adjusted earnings in fiscal 2013 by $0.08 per share. Perrigo now expects fiscal 2013 earnings in the range of $5.53 – $5.73 per share (previous guidance: $5.45 – $5.65 per share). The Zacks Consensus Estimate of $5.56 per share is towards the lower end of the company’s guidance range.

We note that Perrigo has been quite active on the acquisition front lately. In a bid to strengthen its position in the over-the-counter (OTC) retail pet healthcare market, just a few days back Perrigo inked a deal to buy animal health company Velcera, Inc. for $160 million in cash. The deal is expected to close in calendar year 2013.

In Dec 2012, Perrigo acquired privately-held Cobrek Pharmaceuticals, Inc. for approximately $45 million in cash. In Oct 2012, Perrigo had acquired the entire assets of privately-held Sergeant's Pet Care Products, Inc.

Perrigo, which develops, manufactures and distributes OTC and generic prescription pharmaceuticals among others, carries a Zacks Rank #3 (Hold). Other players in the generic market, such as Mylan Inc. (MYL - Analyst Report) and Pernix Therapeutic Holdings, Inc. , carry a Zacks Rank #2 (Buy). Meanwhile, biopharma stock, Valeant Pharmaceuticals (VRX - Snapshot Report) has a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%